Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| My Size, Inc.MYSZ · Entity 8556 | Chief Financial Officer | December 15, 2025 | December 17, 2025 |
| Nasus Pharma LtdNSRX · Entity 7254 | Interim CFO | September 19, 2026 | September 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
My Size, Inc.
Report date December 15, 2025 · Filed December 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,500 |
Reported balance
After 2025-12-15 transaction · row 1
1 source rowRow 1 · 2025-12-15 · Grant · Acquired 30,000 · Balance 32,500 F1: Restricted shares granted under the My Size, Inc. 2017 Equity Incentive Plan. F2: The restricted shares vest in three equal annual installments, with 1/3 vesting on each of January 1, 2026, January 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service to the Issuer as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares granted under the My Size, Inc. 2017 Equity Incentive Plan.
F2: The restricted shares vest in three equal annual installments, with 1/3 vesting on each of January 1, 2026, January 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service to the Issuer as of each vesting date.
Nasus Pharma Ltd
Report date September 19, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2029-11-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-19 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Options to purchase 24,680 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on November 28, 2019. As of September 18, 2026, 24,680 options remain outstanding, all of which are vested and exercisable, at an exercise price of $1.2264 per share, expiring November 28, 2029. |
| Share options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05 · Expires 2035-01-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-19 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Options to purchase 27,460 Ordinary Shares were granted on January 17, 2025, with the total grant vesting in equal quarterly installments of 8.33% commencing on January 17, 2025. As of September 18, 2026, 13,840 are vested and exercisable, at an exercise price of $6.0462 per share, expiring January 17, 2035. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 24,680 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on November 28, 2019. As of September 18, 2026, 24,680 options remain outstanding, all of which are vested and exercisable, at an exercise price of $1.2264 per share, expiring November 28, 2029.
F2: Options to purchase 27,460 Ordinary Shares were granted on January 17, 2025, with the total grant vesting in equal quarterly installments of 8.33% commencing on January 17, 2025. As of September 18, 2026, 13,840 are vested and exercisable, at an exercise price of $6.0462 per share, expiring January 17, 2035.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2025 Filed Dec 17, 2025 16:15 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-028140 · ownership.xml · nonDerivative · entry 1 Elmaliah Oren · CIK 0001713701 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 F1 · shares: Restricted shares granted under the My Size, Inc. 2017 Equity Incentive Plan. F2 · shares: The restricted shares vest in three equal annual installments, with 1/3 vesting on each of January 1, 2026, January 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service to the Issuer as of each vesting date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 16:10 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantOption to purchase Common Stock (right to buy) · Derivative | 150 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001641172-25-014032 · ownership.xml · derivative · entry 2 Elmaliah Oren · CIK 0001713701 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150 Underlying: Common Stock, $.001 par value per share · 150 shares Expires 2025-08-10 F2 · price: Effective June 4, 2025, the Board of Directors of the Company approved a unilateral option repricing, which resulted in the reduction of the exercise price to $1.28 per share, which is the closing price of the Company's common stock on June 4, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 16:10 UTC | My Size, Inc. MYSZ · Entity 8556 | Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 150 | Not disclosed Strike: $8.72 | Not disclosed |
DisclosureSEC source: 0001641172-25-014032 · ownership.xml · derivative · entry 1 Elmaliah Oren · CIK 0001713701 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 150 shares Expires 2025-08-10 F2 · price: Effective June 4, 2025, the Board of Directors of the Company approved a unilateral option repricing, which resulted in the reduction of the exercise price to $1.28 per share, which is the closing price of the Company's common stock on June 4, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 16:20 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-007017 · ownership.xml · nonDerivative · entry 1 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Restricted stock units granted under the My Size, Inc. 2017 Equity Incentive Plan, which vest on January 1, 2025. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 17:05 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantOption to purchase Common Stock (right to buy) · Derivative | 40 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001493152-23-024750 · ownership.xml · derivative · entry 4 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40 Underlying: Common Stock, $.001 par value per share · 40 shares Expires 2024-05-29 F2 · price: Effective July 13, 2023, the Board of Directors of the Company approved a unilateral option repricing, which resulted in the reduction of the exercise price to $1.09 per share, which is the closing price of the Company's common stock on July 13, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 17:05 UTC | My Size, Inc. MYSZ · Entity 8556 | Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 40 | Not disclosed Strike: $26.00 | Not disclosed |
DisclosureSEC source: 0001493152-23-024750 · ownership.xml · derivative · entry 3 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 40 shares Expires 2024-05-29 F2 · price: Effective July 13, 2023, the Board of Directors of the Company approved a unilateral option repricing, which resulted in the reduction of the exercise price to $1.09 per share, which is the closing price of the Company's common stock on July 13, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 17:05 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantOption to purchase Common Stock (right to buy) · Derivative | 1,200 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001493152-23-024750 · ownership.xml · derivative · entry 2 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock, $.001 par value per share · 1,200 shares Expires 2025-08-10 F2 · price: Effective July 13, 2023, the Board of Directors of the Company approved a unilateral option repricing, which resulted in the reduction of the exercise price to $1.09 per share, which is the closing price of the Company's common stock on July 13, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 17:05 UTC | My Size, Inc. MYSZ · Entity 8556 | Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 1,200 | Not disclosed Strike: $26.00 | Not disclosed |
DisclosureSEC source: 0001493152-23-024750 · ownership.xml · derivative · entry 1 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 1,200 shares Expires 2025-08-10 F2 · price: Effective July 13, 2023, the Board of Directors of the Company approved a unilateral option repricing, which resulted in the reduction of the exercise price to $1.09 per share, which is the closing price of the Company's common stock on July 13, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 16:22 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantOption to purchase Common Stock (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001213900-20-021621 · ownership.xml · derivative · entry 1 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, $.001 par value per share · 30,000 shares Expires 2025-08-10 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. All 30,000 options shall vest on November 26, 2020. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantOption to purchase Common Stock (right to buy) · Derivative | 1,000 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 6 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock, $.001 par value per share · 1,000 shares Expires 2025-05-29 F4 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC | My Size, Inc. MYSZ · Entity 8556 | Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 1,000 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 5 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 1,000 shares Expires 2024-05-29 F4 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantOption to purchase Common Stock (right to buy) · Derivative | 667 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 4 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock, $.001 par value per share · 667 shares Expires 2024-09-06 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of September 6, 2024. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC | My Size, Inc. MYSZ · Entity 8556 | Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 667 | Not disclosed Strike: $13.65 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 3 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 667 shares Expires 2023-09-06 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of September 6, 2024. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantOption to purchase Common Stock (right to buy) · Derivative | 667 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 2 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock, $.001 par value per share · 667 shares Expires 2023-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC | My Size, Inc. MYSZ · Entity 8556 | Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 667 | Not disclosed Strike: $18.15 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 1 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 667 shares Expires 2022-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 21:31 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantOption to purchase Common Stock (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001213900-19-009984 · ownership.xml · derivative · entry 1 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, $.001 par value per share · 15,000 shares Expires 2024-05-30 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. All 15,000 options shall vest on December 31, 2019. Read SEC document |
| September 06, 2018 Filed Jan 30, 2019 16:19 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantOption to purchase Common Stock (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001213900-19-001443 · ownership.xml · derivative · entry 1 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2023-09-06 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. All 10,000 options shall vest on September 6, 2019. Read SEC document |
| July 24, 2017 Filed Aug 3, 2017 06:58 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantOption to purchase Common Stock (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001213900-17-008170 · f4072417elmaliah_mysizeinc.xml · derivative · entry 1 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2022-07-24 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. All 10,000 options shall vest on July 24, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.